| 1 |
34430783 | In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology. | 2021 Aug |
3 |
| 2 |
31645655 | Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir. | 2020 Jan |
3 |
| 3 |
31291311 | Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C. | 2019 |
1 |
| 4 |
29589331 | Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. | 2018 Jun |
2 |
| 5 |
26153443 | Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. | 2016 |
1 |
| 6 |
26177803 | Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions. | 2015 Dec |
1 |
| 7 |
26744738 | Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection. | 2015 Nov |
1 |